Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation

Publisher： Karger

E-ISSN： 1664-5502|7|1|21-30

ISSN： 1664-3828

Source： Cardiorenal Medicine, Vol.7, Iss.1, 2016-08, pp. : 21-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

By  

Cardiorenal Medicine, Vol. 7, Iss. 3, 2017-04 ,pp. : 188-197

Karger

Access to resources Recommend Favorite

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-11 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-08 ,pp. : 45-54

Karger

Access to resources Recommend Favorite

The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors

By  

Blood Purification, Vol. 29, Iss. 2, 2010-01 ,pp. : 86-92

Karger

Access to resources Recommend Favorite

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 235-247

Karger

Access to resources Recommend Favorite